Baird's Brian Skorney Comments on Regenxbio Inc. (RGNX): 'We also think it's favorable that REGENXBIO is able to learn from Elevidys' faults'
Tweet Send to a Friend
Baird analyst Brian Skorney reiterated an Outperform rating and $39.00 price target on Regenxbio Inc. (NASDAQ: RGNX)The analyst comments "No ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
